Robin LaChapelle
CIK: 0002009136
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ArriVent BioPharma, Inc.
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Oct 30, 2026AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct4.6K shares at avg. $2.28$10K - Oct 30, 2026AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct410 shares at avg. $2.28$935.415 - Oct 30, 2026AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct16.3K shares at avg. $3.65$59K - Oct 30, 2026AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct17.6K shares at avg. $6.24$110K - Oct 30, 2026AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct1.8K shares at avg. $2.28$4K - Feb 2, 2026AVBP
ArriVent BioPharma, Inc.
Award(A)DirectStock Option (right to buy)
130K shares- - Jul 11, 2025AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct2.1K shares at avg. $2.28$5K - Jul 11, 2025AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct2.6K shares at avg. $2.28$6K - Jul 11, 2025AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct6.5K shares at avg. $2.28$15K - Feb 3, 2025AVBP
ArriVent BioPharma, Inc.
Award(A)DirectStock Option (right to buy)
120K shares- - Sep 19, 2024AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct12.4K shares at avg. $3.65$45K - Sep 19, 2024AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct2.5K shares at avg. $2.28$6K - Sep 19, 2024AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct7.2K shares at avg. $2.28$16K - Sep 19, 2024AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct2.9K shares at avg. $2.28$7K - Sep 19, 2024AVBP
ArriVent BioPharma, Inc.
Exercise(M)Direct2.7K shares at avg. $6.24$17K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 4,550 | $2.28 | $10,381 | Direct |
| Oct 30, 2026 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 410 | $2.28 | $935 | Direct |
| Oct 30, 2026 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 16,265 | $3.65 | $59,374 | Direct |
| Oct 30, 2026 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 17,648 | $6.24 | $110,055 | Direct |
| Oct 30, 2026 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 1,820 | $2.28 | $4,152 | Direct |
| Feb 2, 2026 | AVBP ArriVent BioPharma, Inc. | Award(A) Stock Option (right to buy) | 130,000 | - | - | Direct |
| Jul 11, 2025 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 2,050 | $2.28 | $4,674 | Direct |
| Jul 11, 2025 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 2,600 | $2.28 | $5,928 | Direct |
| Jul 11, 2025 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 6,503 | $2.28 | $14,827 | Direct |
| Feb 3, 2025 | AVBP ArriVent BioPharma, Inc. | Award(A) Stock Option (right to buy) | 120,000 | - | - | Direct |
| Sep 19, 2024 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 12,364 | $3.65 | $45,129 | Direct |
| Sep 19, 2024 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 2,471 | $2.28 | $5,634 | Direct |
| Sep 19, 2024 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 7,164 | $2.28 | $16,334 | Direct |
| Sep 19, 2024 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 2,867 | $2.28 | $6,537 | Direct |
| Sep 19, 2024 | AVBP ArriVent BioPharma, Inc. | Exercise(M) | 2,700 | $6.24 | $16,848 | Direct |
1-15 of 15 transactions
About LaChapelle Robin
LaChapelle Robin (SEC CIK 0002009136) files insider reports with the SEC as Chief Operating Officer of ArriVent BioPharma, Inc. (AVBP).
Signal8 holds 5 ownership filings by LaChapelle Robin, all Form 4s, filed between Sep 23, 2024 and Nov 2, 2026. Those filings report 15 transactions, from Sep 19, 2024 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LaChapelle Robin's filings is in MIAMI, FL.
Recent filings by LaChapelle Robin
- Oct 30, 2026: Option exercises of AVBP shares (5 lines, Form 4, code M).
- Feb 2, 2026: Grant or award of AVBP derivative securities (Form 4, code A).
- Jul 11, 2025: Option exercises of AVBP shares (3 lines, Form 4, code M).
- Feb 3, 2025: Grant or award of AVBP derivative securities (Form 4, code A).
- Sep 19, 2024: Option exercises of AVBP shares (5 lines, Form 4, code M).
Other insiders filing for ArriVent BioPharma, Inc. (AVBP)
- Parsey Merdad, Director
- Peterson Kristine, Director
- Hohneker John, Director
- Nolet Chris, Director
- Lutzker Stuart, President of R&D
- Kung Winston, Chief Financial Officer